In clinical practice, IL‐17A antibodies (Secukinumab and Ixekizumab), and IL‐17 receptor A inhibitors (Brodalumab) could reduce the K17 expression,35 which are effective and safe therapies for psoriasis. The gene discussed is IL17A; the disease is psoriasis.